Avexa discovers drugs to treat vexing ailments. The pharmaceutical and research company works on the discovery and development of drugs for the treatment of infectious diseases, specifically HIV and antibiotic-resistant strains of bacteria. Avexa has worked on collaborative projects with Victorian College of Pharmacy, The Shanghai Institute of Organic Chemistry, North Carolina State University, and Georgetown University, among other institutions. The company was formed in 2004 when it was spun off from Australian drug discovery and biotechnology development company Amrad. Plans to merge with drugmaker Progen Pharmaceutical were canceled in 2009.

Alexion Pharmaceuticals was founded in 1992 and is headquartered in Cheshire, Connecticut. Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and delivers drug therapies for patients with various medical conditions. It primarily engages in the discovery, development, and commercialization of biologic therapeutic products for the treatment of various disease states, including hematologic and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. The company primarily markets Soliris (eculizumab) in the United States and Europe for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder. It is also evaluating other indications for Soliris, as well as other formulations of eculizumab for additional clinical indications. In addition, the company is developing Anti-CD200 antibody for the treatment of B-Cell Chronic Lymphocytic Leukemia, a cancer that results from expansion of B-lymphocytes and other cancers.Alexion Pharmaceuticals drug programs include Eculizumab (intravenous), a phase II product candidate for atypical HUS, presensitized renal transplant, myasthenia gravis, multifocal motor neuropathy, dense deposit disease, catastrophic antiphospholipid syndrome, and cold agglutinin disease; CD200 Mab, which is in phase I/II clinical trial for the treatment of chronic lymphocytic leukemia and in preclinical stage for the treatment of multiple myeloma; and Eculizumab (new formulation) that is under phase I/II clinical trial for the treatment of asthma. Its customers include specialty distributors and specialty pharmacies who supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, and other health care providers and distributors.

Spectral Diagnostics Inc. company was founded in 1991 and is based in Toronto, Canada. Spectral Diagnostics Inc. operates in the in vitro diagnostic testing market. The company focuses on the development, manufacture, and sale of diagnostic tests that provide information to physicians. Its products include EAA Endotoxin Activity Assay, a diagnostic test in the field of sepsis; and RapidWN West Nile Virus IgM Test, an assay that helps physicians in obtaining diagnostic information regarding exposure to the West Nile virus. The company also offers other proprietary biochemicals, including monoclonal antibodies and recombinant proteins. Spectral Diagnostics Inc. has operations primarily in Canada, the United States, and Europe.

Diversa Limited company has developed biosensor technology, drawing on work from the fields of biotechnology, nanotechnology, and electronics. Its primary technology is the Ion Channel Switch, a biosensing device. The Ion Channel Switch, or ICS, technology was developed using a membrane that acts as a switch, triggering an electrical current in the presence of particular molecules. Diversa plans to use the technology in point-of-care diagnostic products. The ICS was developed from research done by the Australian Membrane and Biotechnology Research Institute (AMBRI), the University of Sydney, and others.

BBI Holdings Plc, through its subsidiaries, engages in the development and manufacture of noninvasive lateral flow tests, and the distribution of diabetes products in the United Kingdom and internationally. It operates in three divisions: Diagnostics, Enzymes, and Healthcare. The Diagnostics division involves in the development, manufacture, supply of reagents. The Enzymes engages in the manufacturer and supply of specialist natural enzymes to the medical diagnostics industry. The Healthcare segment involves in the sale and marketing of GlucoGel, a dextrose gel used by diabetes patients when they experience hypoglycaemia; and development of diabetes care product portfolio. The company was founded in 1986 and is headquartered in Cardiff, the United Kingdom. As of February 12, 2008, BBI Holdings plc operates as a subsidiary of Inverness Medical Innovations Inc.

Kreatech Biotechnology company develops tools used by pharmaceutical companies and medical researchers to detect and label RNA, DNA, and proteins. Its labeling kits, DNA probes, and other products are used in applications such as drug development and the diagnosis of disease. The company's investors include 3i Group, Alafi Capital, and Life Sciences Partners. Kreatech has formed alliances with many pharmaceutical and instrumentation firms, including heavyweights such as GE Healthcare Bio-Sciences and PerkinElmer.

China Sky One Medical, Inc. is engaged in the development, manufacture, marketing and sale of over-the-counter, branded nutritional supplements and over-the-counter plant and herb based pharmaceutical and medicinal products. Its principal products are external use Traditional Chinese Herbal Remedies/Medicines (TCM). The Company is also an integrated manufacturer, marketer and distributor of external use Chinese medicine products sold primarily in China and through Chinese domestic pharmaceutical chains. The Company sells both its own manufactured products, as well as medicinal and pharmaceutical products manufactured by others in China. All of its business is conducted through its wholly owned subsidiary, American California Pharmaceutical Group, Inc. (ACPG) which, in turn, wholly owns Harbin Tian Di Ren Medical Science and Technology Company (TDR). On April 3, 2008, TDR completed its acquisition of Heilongjiang Tianlong Pharmaceutical, Inc.

Janssen has gone totally mental. A US-based arm of Johnson & Johnson'sglobal pharmaceuticals segment, Janssen focuses exclusively on treatments for mental health conditions. Its flagship offering Risperdal combats bipolar mania and schizophrenia, as well as irritability associated with autism. A long-acting injectable version of the drug, called Risperdal Consta, is approved as a treatment for schizophrenia. With its sister company Johnson & Johnson Pharmaceutical Research & Development, the company is working on potential drugs for a range of psychiatric problems, including psychosis, sleep disorders, attention deficit/hyperactivity disorder, depression, and substance abuse.

Samaritan Pharmaceuticals, Inc. was founded in 1994 and is based in Las Vegas, Nevada. Samaritan Pharmaceuticals, Inc. (Samaritan) is an entrepreneurial biopharmaceutical company, focused on commercializing therapeutic products to relieve the suffering of patients with Alzheimer's disease, cancer, cardiovascular disease, human immunodeficiency virus (HIV), and Hepatitis C. Samaritan also focuses on commercializing its acquired marketing and sales rights to sell marketed revenue-generating products, in Greece, and/or various Eastern European countries. The Company has partnered its oral entry inhibitor HIV drug SP-01A, a drug that has demonstrated efficacy, in Phase II clinical trials, with Pharmaplaz, Ireland to advance to Phase III clinical trials. In addition, it focuses on commercializing three market drug candidates with late-stage preclinical development programs.

Ore Pharmaceuticals Inc. company was founded in 1994 and is headquartered in Cambridge, Massachusetts. Ore Pharmaceutical Holdings Inc., through its wholly owned subsidiary, Ore Pharmaceuticals Inc., operates as a drug development company in the United States. Its drug candidates include GL1001, the lead drug candidate that completed a multiple ascending dose Phase I clinical trial, for the treatment of inflammatory bowel disease; tiapamil for treatment of diseases of central nervous system, primarily focused on cognition and memory; and romazarit, a clinical-stage drug candidate for the treatment of metabolic indications, such as obesity.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.